Page last updated: 2024-11-12

flucloronide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

flucloronide: synthetic glucocorticoid with anti-inflammatory properties; minor descriptor (75-83); on-line & Index Medicus search PREGNADIENETROLS (75-83); RN given refers to (6alpha,11beta,16alpha)-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID20054914
CHEMBL ID461332
CHEBI ID135787
SCHEMBL ID6701
MeSH IDM0262510

Synonyms (38)

Synonym
D04201
3693-39-8
fluclorolone acetonide (inn)
flucloronide (usan)
flucloronide
CHEBI:135787
fluclorolone acetonide
CHEMBL461332
rs-2252
fluclorone acetonide [dcit]
mg258kta37 ,
acetonide de fluclorolone [inn-french]
flucloroloni acetonidum
acetonido de la fluclorolona [inn-spanish]
fluclorolone acetonide [inn]
acetonido de la fluclorolona
9,11beta-dichloro-6alpha-fluoro-16alpha,17,21-trihydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone
einecs 223-010-9
pregna-1,4-diene-3,20-dione, 9,11-dichloro-6-fluoro-21-hydroxy-16,17-((1-methylethylidene)bis(oxy))-, (6alpha,11beta,16alpha)-
rs 2252
fluclorone acetonide
unii-mg258kta37
flucloronide [usan]
acetonide de fluclorolone
flucloroloni acetonidum [inn-latin]
fluclorolone acetonide [who-dd]
flucloronide [mi]
fluclorolone acetonide [mart.]
pregna-1,4-diene-3,20-dione, 9,11-dichloro-6-fluoro-21-hydroxy-16,17-((1-methylethylidene)bis(oxy))-, (6.alpha.,11.beta.,16.alpha.)-
SCHEMBL6701
DB08973
Q5462615
flucloroloneacetonide
(1s,2s,4r,8s,9s,11s,12r,13s,19s)-11,12-dichloro-19-fluoro-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
EN300-19744561
(1s,2s,4r,8s,9s,11s,12r,13s,19s)-11,12-dichloro-19-fluoro-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosa-14,17-dien-16-one
DTXSID001043281
AKOS040746833
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
21-hydroxy steroid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID409951Inhibition of human liver MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID409946Inhibition of human recombinant MAOB at 100 uM by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (12.50)18.7374
1990's0 (0.00)18.2507
2000's2 (25.00)29.6817
2010's5 (62.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.02 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (25.00%)5.53%
Reviews1 (12.50%)6.00%
Case Studies3 (37.50%)4.05%
Observational0 (0.00%)0.25%
Other2 (25.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]